The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells <i>in vitro</i>.

导出 LinkOut

翻译打印收藏纠错

第一作者： Narjis,Fatima

第一单位： Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, Australia.;School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia.

作者： Narjis,Fatima ^[1] ; Yandong,Shen ^[1] ; Kyle,Crassini ^[2] ; Olivia,Burling ^[3] ; Lauren,Thurgood ^[3] ; Edwin J,Iwanowicz ^[4] ; Henk,Lang ^[4] ; Donald S,Karanewsky ^[4] ; Richard I,Christopherson ^[5] ; Stephen P,Mulligan ^[1] ; O Giles,Best ^[6]

作者单位： Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, Australia.;School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia. ^[1] Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, Australia. ^[2] Flinders Health and Medical Research Institute, Department of Genetics and Molecular Medicine, College of Medicine and Public Health, Flinders University, Camperdown, Australia. ^[3] Madera Therapeutics, LLC, Cary, North Carolina, USA. ^[4] School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia. ^[5] Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Camperdown, Australia.;School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia.;Flinders Health and Medical Research Institute, Department of Genetics and Molecular Medicine, College of Medicine and Public Health, Flinders University, Camperdown, Australia. ^[6]

关键词 Chronic lymphocytic leukemia ClpP (mitochondrial ATP-dependent Caseinolytic protease P subunit)TR-compounds imipridone tumor microenvironment venetoclax